With over 80 disease subtypes and new treatments approved every year, lymphoma and myeloma management is challenging and exciting. The Lymphoma/Myeloma team is a clinical research team combining the expertise from many specialties to offer the best treatment available to our patients, whether it’s standard or experimental. The treatment approach is highly individualized and ranges from surveillance, to targeted therapy, to the latest in immunotherapy, such as chimeric antigen receptor T-cell (CAR T-cell) therapy and immune-redirecting agents.
As academic physicians, we conduct original research to improve the care of our patients. We collaborate with scientists at the University of Arizona Cancer Center and other institutions to write clinical trials that use disease biology to guide treatment and to address unmet needs, such as better and more tolerable treatments for older Americans. We also develop models of incorporating integrative care into cancer treatment, in the field of Integrative Oncology.
Our team has made significant contributions to lymphoma care, including improving lymphoma classification and establishing optimal treatment for both limited and advanced stage aggressive non-Hodgkin’s lymphoma. We lead local and national trials, and actively participate in National Cancer Institute (NCI) National Clinical Trials Network (NCTN). We serve as invited speakers at research and educational meetings, for both colleagues and patients. We will be honored to help you in your cancer journey.
